



SEQUENCE LISTING

<110> LIPPARD, STEPHEN J.
BARNES, CARMEN M.
HASKEL, ARIEL
BARNES, KATIE R.

<120> COORDINATION COMPLEXES HAVING TETHERED THERAPEUTIC
AGENTS AND/OR TARGETING MOIETIES, AND METHODS OF MAKING
AND USING THE SAME

<130> MTV-061.01

<140> 10/755,855
<141> 2004-01-12

<150> 60/439,729
<151> 2003-01-13

<150> 60/505,088
<151> 2003-09-23

<160> 18

<170> PatentIn Ver. 3.3

<210> 1
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

<400> 1
Cys Asn Gly Arg Cys Val Ser Gly Cys Ala Gly Arg Cys
1 5 10

<210> 2
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

<400> 2
Cys Asp Cys Arg Gly Asp Cys Phe Cys
1 5

<210> 3
<211> 7
<212> PRT
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<400> 3

Cys Asn Gly Arg Cys Gly Gly
1 5

<210> 4

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<400> 4

Ser Met Ser Ile Ala Arg Leu
1 5

<210> 5

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<400> 5

Gly Phe Gly Val
1

<210> 6

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<400> 6

Arg Phe Gly Gly
1

<210> 7

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<400> 7

Phe Gly Gly Ser
1

<210> 8

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<400> 8

Phe Gly Gly Ser Val
1 5

<210> 9

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<400> 9

Phe Gly Gly Ser Trp
1 5

<210> 10

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<400> 10

Gly Glu Arg Ile Ser
1 5

<210> 11

<211> 5

<212> PRT

<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 11
Gly Glu Arg Leu Ser
1 5

<210> 12
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 12
Gly Glu Arg Ala Gly
1 5

<210> 13
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 13
Pro Ser Gly Thr Ser
1 5

<210> 14
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 14
Met Ser Gly Thr Gly
1 5

<210> 15
<211> 4
<212> PRT
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<400> 15

Val Ser Gly Thr

1

<210> 16

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<400> 16

Leu Ser Gly Thr

1

<210> 17

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<400> 17

Ile Ser Gly Thr

1

<210> 18

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<400> 18

Cys Gly Phe Glu Cys Val Arg Gln Cys Pro Glu Arg Cys

1

5

10